Liraglutide + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smoking Cessation
Conditions
Smoking Cessation, Weight, Body
Trial Timeline
Nov 29, 2018 → May 25, 2022
NCT ID
NCT03712098About Liraglutide + Placebo
Liraglutide + Placebo is a phase 2 stage product being developed by Novo Nordisk for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT03712098. Target conditions include Smoking Cessation, Weight, Body.
What happened to similar drugs?
17 of 20 similar drugs in Smoking Cessation were approved
Approved (17) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04775082 | Phase 3 | Active |
| NCT03712098 | Phase 2 | Completed |
| NCT03523273 | Phase 2 | Completed |
| NCT02953665 | Phase 2 | Completed |
| NCT02964247 | Phase 3 | Completed |
| NCT02963935 | Phase 3 | Completed |
| NCT03038620 | Approved | Completed |
| NCT02889510 | Phase 3 | Completed |
| NCT02918279 | Phase 3 | Completed |
| NCT02717858 | Phase 1 | Completed |
| NCT02696148 | Phase 1 | Completed |
| NCT02655770 | Approved | Completed |
| NCT02647944 | Phase 2 | Completed |
| NCT02527200 | Phase 3 | Completed |
| NCT02473809 | Approved | Completed |
| NCT02545738 | Approved | Completed |
| NCT02284230 | Phase 2 | Withdrawn |
| NCT01789086 | Phase 1 | Completed |
| NCT01755572 | Approved | Completed |
| NCT02113332 | Phase 2 | Completed |
Competing Products
20 competing products in Smoking Cessation